Neurogene Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 382.6K | $7.71M | 0.00% | Added+193.6% | 2026-03-31 |
| StateStreet | passive | 313.0K | $6.31M | 0.00% | Added+1.7% | 2026-03-31 |
| RenTech | quant | 43.4K | $874.94K | 0.00% | Added+210.0% | 2026-03-31 |
| TwoSigma | quant | 13.9K | $280.04K | 0.00% | Added+15.8% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-11upcoming | -1.38 | — | — |
| 2026-03-24 | -1.24 | -1.13 | +8.69% |
| 2025-11-13 | -1.25 | -0.99 | +20.80% |
| 2025-08-11 | -1.05 | -1.05 | +0.47% |
| 2025-05-09 | -0.92 | -1.08 | -17.39% |
| 2025-03-24 | -1.13 | -0.99 | +12.26% |
| 2024-11-18 | -1.22 | -1.19 | +2.59% |
| 2024-08-09 | -1.03 | -1.09 | -5.62% |
| 2024-05-10 | -0.95 | -1.00 | -5.54% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| NGNE | +5.55% | +28.88% | +37.57% | +66.61% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +2.58% | +33.52% | +41.02% | +53.92% |